Molecular insights into respiratory syncytial virus: Genotyping and characterization in pediatric community-acquired lower respiratory tract infections

Background Respiratory syncytial virus (RSV) continues to pose a considerable global health concern, especially impacting newborns and young children with community-acquired lower respiratory tract infections (LRTIs). Objective This review aims to comprehensively analyze the molecular characteristics, genotyping methods, and epidemiological patterns of RSV, emphasizing its impact on pediatric populations and current developments in prevention strategies. Methods A comprehensive evaluation of current literature examining RSV’s structural components, genetic diversity, clinical manifestations, detection techniques, and vaccine development was conducted. Results RSV, classified into subtypes A and B, demonstrates significant genetic and antigenic variability, particularly in the G glycoprotein gene. The virus causes approximately 33 million cases of acute LRTIs annually in children under five, resulting in 3 million hospitalizations and 118,000 deaths globally. Advanced molecular techniques, including reverse transcription polymerase chain reaction and next-generation sequencing, have enhanced our understanding of RSV’s genetic diversity and transmission dynamics. Recent vaccine developments, particularly those targeting the prefusion F protein, show promising results in clinical trials, including maternal vaccination strategies for protecting neonates. Conclusion Understanding RSV’s molecular characteristics and genetic diversity is crucial for developing effective interventions. Continued surveillance, improved diagnostic techniques, and targeted vaccination approaches are crucial for the management of RSV infections and reducing their global health burden.